HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. A phase 3 study of evolocumab (AMG 145) in statin-treated japanese patients at high cardiovascular risk. 2016;67(13_S):1995.Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. JAMA. Further, complexity of medication regimens has been found to be an important predictor of a patient’s ability to manage medications [There is increasing experience with the subcutaneous (SC) route of administration from biologics in malignancies and inflammatory diseases [Type 2 diabetes mellitus (T2DM), like dyslipidaemia, is a chronic disease for which the majority of daily management rests with the individual patient. of Nev. School of Medicine, Family Medicine. MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia. 2010;63(12):1428–37.Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. 2014;107(3):188–200.Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, et al. Patient Prefer Adherence. Fundam Clin Pharmacol. N Engl J Med. 2005;118(5):27–34.Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. JAMA. N Engl J Med. Complexity perplexity: a systematic review to describe the measurement of medication regimen complexity. Nutr Metab Cardiovasc Dis. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. 1995;155(18):1949–56.Curkendall SM, Thomas N, Bell KF, Juneau PL, Weiss AJ. Definition (CSP) lysine derivative of the active form of enalapril; an angiotensin converting enzyme inhibitor used in … Short communication A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).
Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Antivir Ther. Wierzbicki AS, Viljoen A. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Arch Intern Med.

Patient-related considerations around the acceptability of therapies should therefore play a central role in selecting medications, and have been shown to influence the success of long-term use and clinical outcomes [The dissatisfaction of patients to insulin, in particular, which typically necessitates administration of multiple daily doses, led to the concept of “psychological insulin resistance” [The complexity of medication management is one of the key considerations which impact the ability and willingness of patients with T2DM to initiate and adhere to prescribed therapies. Adv Ther. Evolocumab for treating primary hypercholesterolemia and mixed dyslipidemia Accessed May 2017; available at: National Institute for Health and Care Excellence 2016. 2013;4(2):175–94.Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. The cardiovascular and metabolic therapeutic areas have recently benefited from a number of advances in drug therapy, in particular protease proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incretin-based therapies, respectively. Contraindications include pregnancy, coadministration with strong CYP3A4 inhibitors (lomitapide exposure increased 27-fold), moderate-to-severe hepatic impairment or active liver disease including persistent increased levels of serum transaminases